Patent Attorney's Docket No. <u>010830-117</u>

RECEIVED

IN THE UNITED STATES PATENT A	ND TRADEMARI	K OFFICE	FEB 1/5 2002
Patent Application of)		422	TECH CENTER 1600/2900
Krzysztof MASTERNAK et al.)	Group Art Unit: 1	1023	:
Application No.: 09/840,243)	Examiner: Unassig	gned	
Filed: April 24, 2001			
For: NEW TRANSCRIPTION FACTOR OF) MHC CLASS II GENES, SUBSTANCES) CAPABLE OF INHIBITING THIS NEW) TRANSCRIPTION FACTOR AND) MEDICAL USES OF THESE) SUBSTANCES)			• .
RESPONSE TO NOTICE TO COMPLETE REQUIREMENTS AND PRELIMINARY AM Assistant Commissioner for Patents Workington, D.C., 20231	4DEMA Y WITH SEQUEN ENDMENT TRAN	CE LISTING	ETTER
Washington, D.C. 20231 Sir:			
Enclosed is a Response to Notice to Comply with Preliminary Amendment for the above-identified pate	h Sequence Listing lent application.	Requirements	and
[] A Petition for Extension of Time is also en	nclosed.		
[] A Terminal Disclaimer and a check for [requisite Government fee are also enclose	a.		
[X] Also enclosed is a <u>Declaration Pursuant to copy of Sequence Listing</u> , a diskette conta of the Notice to Comply dated December	o 37 C.F.R. §§ 1.82 aining the Sequence	21825, a pape listing, and a	<u>er</u> <u>copy</u>
[] Small entity status is hereby claimed.			, ,
[] Applicant(s) request continued examination [] \$370.00 (279) [] \$740.00 (179) fee due	under 37 C.P.R. 8	1.17(0).	
[] Applicant(s) previously submitted requested.	_, on, for which	continued exa	amination is

[] Applicant(s) request suspension of action by the Office until at least _, which does not exceed three months from the filing of this RCE, in accordance with 37 C.F.R. § 1.103(c). The required fee under 37 C.F.R. § 1.17(i) is enclosed.

[] A Request for Entry and Consideration of Submission under 37 C.F.R. § 1.129(a) (146/246) is also enclosed.

[X] No additional claim fee is required.

[] An additional claim fee is required, and is calculated as shown below:

	No. OF CLAIMS	HIGHEST NO. OF CLAIMS PREVIOUSLY PAID FOR	EXTRA CLAIMS	RATE	ADDT'L FEE
Total Claims	76	MINUS 76 =	-0-	× \$18.00 (103) =	-0-
Independent Claims	10	MINUS 10 =	-0-	× \$84.00 (102) =	-0-
If Amendment adds mu	ltiple depend	ent claims, add \$280).00 (104)		
Total Amendment Fee			•		
If small entity status is	claimed, sub	tract 50% of Total A	mendment Fe	ee	

ſ	1	A claim	fee in t	he amount	of \$	is	enclosed.
---	---	---------	----------	-----------	-------	----	-----------

[] Charge \$_____to Deposit Account No. 02-4800.

The Commissioner is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17, 1.20(d) and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in duplicate.

Respectfully submitted,


BURNS, DOANE, SWECKER & MATHIS, L.L.P.

Susan M. Dadio

Registration No. 40,373

P.O. Box 1404 Alexandria, Virginia 22313-1404 (703) 836-6620

Date: February 13, 2002





United States Patent and Trademark Office

TECH CENTER 1600/2900

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 2023I
WWW.USDIO.GOV

APPLICATION NUMBER

FILING/RECEIPT DATE

FIRST NAMED APPLICANT

ATTORNEY DOCKET NUMBER

09/840,243

04/24/2001

Krzysztof Masternak

010830-117

21839 BURNS DOANE SWECKER & MATHIS L L P POST OFFICE BOX 1404 ALEXANDRIA, VA 22313-1404 CONFIRMATION NO. 3494 FORMALITIES LETTER

OC000000007191693*

Date Mailed: 12/13/2001

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

• A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing." Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase Patentin Software, call (703) 306-2600
- For Patentin Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

A copy of this notice MUST be returned with the reply.

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE